Mutated cancer cells presenting tumor antigens by human leukocyte antigen class I (HLA-I) could be identified and killed by CD8+ T cells, and low heterozygosity of HLA-I has been associated with poor outcomes for melanoma patients treated with anti-PD-1 (16). Here, PDCD1 is linked to cancer.